Secondary Logo

Journal Logo

March-April 2003 - Volume 26 - Issue 2
pp: 95-183



Immune Effects of Escalating Doses of Granulocyte-Macrophage Colony-Stimulating Factor Added to a Fixed, Low-Dose, Inpatient Interleukin-2 Regimen: A Randomized Phase I Trial in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Smith, John W. II; Kurt, Robert A.; Baher, Angelo G.; More

Journal of Immunotherapy. 26(2):130-138, March-April 2003.

Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer

Crombet, Tania; Torres, Leonel; Neninger, Elia; More

Journal of Immunotherapy. 26(2):139-148, March-April 2003.

Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma

Ridolfi, Laura; Ridolfi, Ruggero; Riccobon, Angela; More

Journal of Immunotherapy. 26(2):156-162, March-April 2003.

Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells

Dols, Annemieke; Meijer, Sybren L.; Hu, Hong-Ming; More

Journal of Immunotherapy. 26(2):163-170, March-April 2003.